Jeffrey R. Binder, CEO of Biomet, attributed the lower-than-expected increase to a deceleration of procedural growth in the market. However, he remains optimistic about long-term growth.
The company reported a 3 percent and 7 percent increase in orthopedic reconstructive sales in the world and U.S., respectively. Knee sales increased by 4 percent, extremity sales increased by 25 percent, and sports medicine sales grew by 15 percent worldwide.
Read the release on Biomet’s 1Q FY report.
Read other coverage on Biomet:
– Biomet Announces 4Q FY 2010 Financial Results
– Biomet Acquires Massachusetts’ Cytosol Laboratories
– Biomet Sports Medicine Mobile Learning Center to Provide Product Demonstration and Education
